BP 897

Cat. No.:	HY-114085
CAS No.:	192384-87-5
Molecular Formula:	$C_{26}H_{31}N_3O_2$
Molecular Weight:	417.54
Target:	Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM)[1].	
IC_{50} & Target	D_2 Receptor	D_3 Receptor
In Vitro	BP 897 also displays low affinities at D1 and D4 receptors (K_i=3 and 0.3 μM, respectively), as well as at α1 and α2 adrenergic receptors (K_i=60 and 83 nM, respectively), 5HT1A and 5HT7 receptors (K_i=84 and 345 nM, respectively), and negligible affinities (K_i>1 μM) atmuscarinic, histamine and opiate receptors[1]. In NG 108-15 cells expressing the human D3 receptor, BP 897 inhibits forskolin-induced cyclic AMP accumulation with an EC_{50} of 1 nM. BP 897 activates mitogenesis and this response is antagonized by the preferential D3 receptor antagonist Nafadotride (1 μM). BP 897 also partially antagonized the response induced by quinpirole (10 nM)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Pilla M, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist [published correction appears in Nature 1999 Sep 23;401(6751):403]. Nature. 1999;400(6742):371-375.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA